Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aesthetics Market: Fillers May Offer Bright Spot in Tough Times

Executive Summary

Signs point to a suppressed market for all aesthetics products for at least the remainder of 2009, but there's some evidence that dermal fillers have escaped the worst effects of the economic downturn. The American Society of Plastic Surgeons reports that while there was a 5% decrease in facelifts in 2008, the use of hyaluronic acid fillers was up by 6%, although dermal filler sales started to take a hit in the final quarter of the year.

You may also be interested in...



Cosmetic Dermatology Thrives in Spite of Economy

While other medical device sectors, such as orthopedics and invasive plastic surgery, experienced a downturn in elective procedures in 2009, cosmetic dermatology procedures--including Botox and facial filler injections--continue on their upward trend. This fact was emphasized by the record attendance at the American Academy of Dermatology summer meeting held in Chicago in August 2010.

Botox vs. Dysport: REMS is a New wrinkle in Big Market

A marketing battle with an unusual twist is brewing between Allergan's popular anti-wrinkle agent Botox and new-to-the-block Dysport, from Ipsen-Medicis. Both sides are citing their REMS (Risk Evaluation and Mitigation Strategy) as a key competitive advantage.

Medical Dermatology Gets Under VCs' Skin

In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel